|
Ireland Nephrology and Urology Devices Investment Opportunities, Analysis and ... - SBWire (press release) |
 |
 |
|
Naperville, IL -- (SBWIRE) -- 06/29/2012 -- Ireland Nephrology and Urology Devices Investment Opportunities, Analysis and Forecasts to 2018 a new report by provides key market data on the Ireland Nephrology and Urology Devices market. The report provides value (USD million), volume (units) and average price (USD) data for each segment and sub-segment within three market categories – Incontinence Devices, Lithotripters and Renal Dialysis Equipment. The report also provides company shares and distribution shares data for each of the aforementioned market categories. The report is supplemented with global corporate-level profiles of the key market participants with information on key recent developments.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Global Markets Direct’s team of industry experts.
Scope
- Nephrology and Urology Devices market size and company share data for market categories – Incontinence Devices, Lithotripters and Renal Dialysis Equipment.
- Annualized market revenues (USD million), volume (units) and average price (USD) data for each of the segments and sub-segments within three market categories. Data from 2004 to 2011, forecast forward for 7 years to 2018.
- 2011 company shares and distribution shares data for each of the three market categories.
- Global corporate-level profiles of key companies operating within the Ireland Nephrology and Urology Devices market.
- Key players covered include Fresenius Medical Care AG & Co. KGaA, Gambro AB, Svenska Cellulosa Aktiebolaget SCA, Baxter International Inc., HARTMANN GROUP, B. Braun Melsungen AG and others.
Reasons to buy
- Develop business strategies by identifying the key market categories and segments poised for strong growth.
- Develop market-entry and market expansion strategies.
- Design competition strategies by identifying who-stands-where in the Ireland Nephrology and Urology Devices competitive landscape.
- Develop capital investment strategies by identifying the key market segments expected to register strong growth in the near future.
- What are the key distribution channels and what’s the most preferred mode of product distribution – Identify, understand and capitalize.
Companies Mentioned
Fresenius Medical Care AG & Co. KGaA Gambro AB Svenska Cellulosa Aktiebolaget SCA Baxter International Inc. HARTMANN GROUP B. Braun Melsungen AG ONTEX International N.V. Coloplast A/S First Quality Enterprises, Inc. Kimberly-Clark Corporation Teleflex Incorporated Covidien plc Dornier MedTech GmbH STORZ MEDICAL AG Medline Industries, Inc. Siemens Healthcare
To view the detailed table of contents for this report please visit: http://www.reportstack.com/product/67562/ireland-nephrology-and-urology-devices-investment-opportunities-analysis-and-forecasts-to-2018.html
|
|
New dialysis center opens in Waukegan - Lake County News Sun |
|
|
|
NEWS-SUN STAFF REPORT June 29, 2012 3:58PM
Updated: June 30, 2012 2:16AM
WAUKEGAN — Fresenius Medical Care’s Waukegan Harbor dialysis center has opened just west of the city’s downtown at 110 N. West St.
Officials with Fresenius Medical Care North America, headquartered in Waltham, Mass., said the 21-station clinic will provide treatment to the region’s growing population of patients with chronic kidney disease.
Dialysis is a process that cleans waste products from the blood, removes extra fluids and controls the body’s chemistry when a person’s kidneys fail. Dialysis patients usually require treatment on an ongoing basis unless they receive a kidney transplant.
“Patients typically receive dialysis three times a week for four hours each session. Given the frequency and duration of treatment, we do all we can to ensure our patients’ comfort and help them integrate their appointments into their daily lives,” said Mercy Saavedra, R.N., clinical manager for Fresenius Medical Care.”
Dr. Rakhi Khanna, a nephrologist with North Suburban Nephrology in Gurnee, serves as medical director at the new Medicare-certified facility. Fresenius is the nation’s leading network of dialysis facilities,
“The reaction from the Waukegan community has been wonderful,” said Dr. Khanna. “Our patients — some of whom previously had to travel as far as Antioch for treatment — were happy to see us open our doors.”
The Fresenius clinic offers patients a full range of dialysis-related medical services including a kidney transplant support program, nutrition counseling, bone disease management and social worker support. The facility also features technology, such as touch-screen dialysis station monitors that allow clinical staff to enter and securely track patient information.
|
|
|
Bucks ambulance owner indicted in $5.4M fraud - Philadelphia Inquirer |
|
|
|
A Bucks County man has been indicted in a scheme that bilked Medicare of more than $5.4 million.
William V. Hlushmanuk, 35, of Churchville was charged in a 23-count health care fraud indictment that was unsealed today by the U.S. Attorney General's office.
Hlushmanuk, also known as "Bill Le," allegedly started the Starcare Ambulance Company in 2006 to transport kidney dialysis patients.
Because Hlushmanuk had a criminal record that included conviction for burglary, assault and firearms violations, he was ineligible to operate the company under his own name, so he used a straw owner identified in documents only as B.R.
Starcare employees instructed patients who could otherwise walk to climb onto stretchers for their three-times-a-week trips to dialysis clinics. Each round-trip averaged $400 allowing the company to continuously bill Medicare for the unnecessary rides, according to investigators.
During the course of five years, Starcare billed over $5,443,315.72 in rides to the U.S. government.
The indictment, which demands the return of the money, along with a 2006 Hummer, charges 21 counts of health care fraud, one count of conspiring to commit health care fraud and one count of aiding and abetting in a false statement relating to a health care matter.
Contact staff writer Sam Wood at 215-854-2796 or
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
.
Follow the Inquirer at www.Twitter.com/PhillyInquirer and www.Facebook.com/PhillyInquirer
|
|
FDA Places GranuFlo, NaturaLyte Under Serious Recall Category - Renal Business Today |
|
|
|
NEW YORK—GranuFlo and NaturaLyte, both Fresenius Medical dialysis concentrates, have been classified by the U.S. Food and Drug Administration (FDA) as Class I recall products, placing them in the agency's most serious medical device recall category.
In March 2012, Fresenius issued an Urgent Product Notification warning its customers that GranuFlo and NaturaLyte are associated with elevated bicarbonate levels, a significant risk factor for cardiac arrest. Parker Waichman LLP first reported on these issues in a press release issued by the firm on June 21, 2012.
According to the FDA, Class I recalls are the most serious type of recall and involve situations in which there is a reasonable probability that use of a product will cause serious adverse health consequences or death.
GranuFlo and NaturaLyte are alkaline substance administered to dialysis patients to neutralize the acid that builds up in the blood. The products are administered in conjunction with bicarbonate, and contain acetate, an ingredient that the body converts to bicarbonate. However, GranuFlo and NaturaLyte contain far more acetate than rival products, and thus result in more bicarbonate in the body.
According to the Times, Fresenius is being investigated for failing to warn its customers about the serious risks associated with GranuFlo and NaturaLyte. According to the report, Fresenius had issued an internal memo to its own clinics on November 4, 2011, warning that 941 hemodialysis patients experienced cardiac arrest at 667 Fresenius facilities in 2010. The company conducted an analysis of these patients, comparing them to over 80,000 other dialysis patients in the same centers. Overall, the data indicated that excess bicarbonate, or alkalosis, significantly increased the risk of heart problems in hemodialysis patients.
While Fresenius alerted its own physicians and medical directors about the issue, it did not notify the public or the FDA about the findings until the agency received an anonymous copy of the memo and inquired about it. In May, the FDA issued a Safety Communication warning about alkali dosing errors for products like GranuFlo and NaturaLyte in hemodialysis patients. “Given that Fresenius’ actions or inaction raise concerns as to whether Fresenius is capable of appropriately advising facilities using GranuFlo and NaturaLyte Dialysis Products of their inherent danger, FDA’s Class I recall is a welcomed action,” says Matthew McCauley, senior litigation counsel at Parker Waichman LLP. “By taking this action, FDA essentially ordered Fresenius to take the necessary steps to advise ALL, not just Fresenius owned, facilities using GranuFlo and NaturaLyte Dialysis Products that these products are being investigated for serious safety concerns.”
As stated on the FDA website, health care professionals and consumers may report adverse reactions or quality problems they experienced using these products to MedWatch: The FDA Safety Information and Adverse Event Reporting Program either online, by regular mail or by FAX.
|
|
Log in to explore the world's most comprehensive database of dialysis centres for free! 
Professional dialysis recruitment
